CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks [Yahoo! Finance]
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: Yahoo! Finance
The CMTA Board and CMT community are profoundly grateful for the significant contributions of departing board members Phyllis Sanders, Alan Korowitz, Elizabeth Ouellette, and Chris Ouellette as they transition to new roles as special advisors GLENOLDEN, PA / ACCESSWIRE / March 25, 2024 / The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of Bernard Coulie, M.D., Ph.D., and Kevin Marks to its Board of Directors. Bernard Coulie brings a wealth of experience to the CMTA Board. As the CEO and President of Pliant Therapeutics, a NASDAQ-listed biopharmaceutical company focusing on rare and life-threatening fibrotic diseases, Bernard has dedicated over 20 years to the biopharmaceutical industry in both executive leadership as well as board of director roles. His personal connection to CMT, dating back to 1997 when his son was
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.MarketBeat
- Pliant Therapeutics to Participate in Upcoming Investor EventsGlobeNewswire
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceGlobeNewswire
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis [Yahoo! Finance]Yahoo! Finance
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- 3/12/24 - Form 8-K
- PLRX's page on the SEC website